Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Zhonghua Yi Xue Za Zhi ; 102(8): 569-575, 2022 Mar 01.
Artigo em Chinês | MEDLINE | ID: mdl-35196779

RESUMO

Objective: To screen long non-coding RNA (lncRNA) related to the prognosis of cholangiocarcinoma patients, detect its expression in cholangiocarcinoma tissue, and analyze its clinical significance by analyzing The Cancer Genome Atlas (TCGA) database. Methods: Using limma package, survival package, and survival receiver operating characteristic curve (ROC) package of R software to analyze the data of cholangiocarcinoma in TCGA and screen the differentially expressed lncRNAs related to patient survival. Real-time PCR and Fish were used to detect the expression of lncRNA and analyze its correlation with the clinical characteristics of patients. Small interfering RNA was used to knock down the expression of lncRNA GIHCG, and its effect on the migration ability of cholangiocarcinoma cell lines was detected by Transwell. Results: The results of the comprehensive analysis of survival, ROC, and correlation analysis with clinical data showed that lncRNA GIHCG has a significant correlation with lymph node metastasis in patients with cholangiocarcinoma. The expression of lncRNA GIHCG in cholangiocarcinoma tissue is significantly increased, closely related to tumor size and lymph node metastasis. Transwell results showed that lncRNA GIHCG could promote the migration of cholangiocarcinoma cells. Conclusion: The expression of lncRNA GIHCG is significantly increased in cholangiocarcinoma tissues and is closely related to patient survival and lymph node metastasis. It is expected to become a new molecular marker for diagnosing or treating cholangiocarcinoma.


Assuntos
Neoplasias dos Ductos Biliares , Colangiocarcinoma , RNA Longo não Codificante , Animais , Neoplasias dos Ductos Biliares/genética , Ductos Biliares Intra-Hepáticos , Colangiocarcinoma/genética , Regulação Neoplásica da Expressão Gênica , Humanos , Prognóstico , RNA Longo não Codificante/genética , RNA Longo não Codificante/metabolismo
2.
Zhonghua Yi Xue Za Zhi ; 101(4): 286-292, 2021 Jan 26.
Artigo em Chinês | MEDLINE | ID: mdl-33486939

RESUMO

Objective: To evaluate the safety and effectiveness of combined hepatic artery resection for the treatment of hilar cholangiocarcinoma. Methods: We searched Pubmed, The Cochrane Library, Embase, Web of Science, China Knowledge Network, Wanfang Data Resource System, Vip-Chinese Sci-tech Journal System Database, and China Biomedical Literature Database, and collected the randomized controlled studies or retrospective studies on the safety and efficacy of combined hepatic artery resection and non-hepatic artery resection in the treatment of hilar cholangiocarcinoma. The search period is from January 1, 2006 to December 31, 2019. Review Manager 5.3 software was used to analyze the extracted data indicators. Results: A total of 14 articles were collected, and a total of 2 374 patients with hilar cholangiocarcinoma were included in the study. Meta-analysis results showed that the perioperative mortality in the hepatic artery resection (HAR) group was higher than that of the control group (OR=1.70, 95%CI=0.02-2.90, P=0.05), and the total postoperative morbidity rate was higher than that of the control group (OR=1.28, 95%CI= 0.93-1.76, P=0.13), both of which were not statistically significant compared with the control group. Subgroup analysis showed that the incidence of liver failure (OR=1.15, 95%CI= 0.73-1.82, P=0.54), biliary fistula (OR=1.20, 95%CI= 0.78-1.84, P=0.40), and abdominal infection in the two groups (OR=0.98, 95%CI= 0.53-1.83, P=0.95) was without significant difference. The R0 resection rate of the HAR group was higher than that of the control group, and the difference was not statistically significant (OR=1.08, 95%CI=0.66-1.75, P=0.77). The rates of lymph node metastasis in the HAR group were higher than that in the control group (OR= 2.48, 95%CI= 1.05-5.84, P=0.04). One-year(OR=0.48, 95%CI= 0.32-0.72, P=0.000 5), 3-year (OR= 0.51, 95%CI=0.36-0.72, P=0.000 1), and 5-year (OR=0.50, 95%CI=0.35-0.70, P<0.000 1) survival rates of HAR group were lower than those of the control group. The survival rates of patients in HAR group treated with combined chemotherapy drugs after operation were significantly improved (OR= 7.33, P=0.02). Conclusions: The safety of combined HAR treatment for hilar cholangiocarcinoma is acceptable, but poor postoperative survival may be related to the high lymph node metastasis rate. Therefore, it is still necessary to be cautious in carrying out this operation. Combined with adjuvant chemotherapy after surgery may improve survival.


Assuntos
Neoplasias dos Ductos Biliares , Colangiocarcinoma , Tumor de Klatskin , Neoplasias dos Ductos Biliares/cirurgia , Ductos Biliares Intra-Hepáticos , China , Colangiocarcinoma/cirurgia , Hepatectomia , Artéria Hepática , Humanos , Tumor de Klatskin/cirurgia , Estudos Retrospectivos , Resultado do Tratamento
3.
Zhonghua Yi Xue Za Zhi ; 99(16): 1241-1245, 2019 Apr 23.
Artigo em Chinês | MEDLINE | ID: mdl-31060164

RESUMO

Objective: To investigate the effect of estrogen level on Budd Chiari syndrome related hepatocellular carcinoma. Methods: Immunohistochemical method was used to detect estrogen receptor-α and estrogen receptor-ß expression in 38 cases of Budd Chiari syndrome related hepatocellular carcinoma and 50 cases of HBV related hepatocellular carcinoma.Hepatoma cells of Budd Chiari syndrome related hepatocellular carcinoma were exposed to different concentrations of Estrogen for 48 hours. Tetrazolium bromide (MTT) colorimetry was used to analyze cell proliferation activities; cell cycle was analyzed by flow cytometry (FCM); cell apoptosis was analyzed by flow cytometry (FCM) and Casepase-3 activity was measured after induced by adriamycin(ADM). Results: The positive rate of estrogen receptor-α expression in the tissues of Budd Chiari syndrome related hepatocellular carcinoma was 71.05%, which was higher than that (32%)in HBV related hepatocellular carcinoma tissue evidently (P<0.01). The positive rate of estrogen receptor-ß expression in the tissues of Budd Chiari syndrome related hepatocellular carcinoma was 68.4%, which was higher than that (26%)in HBV related hepatocellular carcinoma tissue evidently (P<0.01). With the concentrations of estrogen increasing, MTT Assays showed that estrogen level increased the cell proliferation activities of Budd Chiari syndrome related hepatocellular carcinoma. The number of cells at stage S and G2/M were significantly increased and cells at stage G0/G1 were reduced with the increasing concentrations of estrogen. After being incubated under the different concentrations of estrogen for 48 h, the apoptosis rates decreased gradually and the Casepase-3 activity was significantly reduced with the increasing concentration of estrogen. Conclusions: Estrogenreceptor expression may have an important influence on hepatocellular carcinoma cell biology difference between Budd Chiari syndrome related hepatocellular carcinoma and HBV related hepatocellular carcinoma. Estrogen level can promote cell proliferation and cell cycle, and inhibit the apoptosis of hepatoma cells of Budd Chiari syndrome related hepatocellular carcinoma in vitro, and these effects were increased with the increasing of estrogen level.


Assuntos
Síndrome de Budd-Chiari , Carcinoma Hepatocelular , Neoplasias Hepáticas , Apoptose , Estrogênios , Humanos
4.
Sci Total Environ ; 407(1): 197-203, 2008 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-18817945

RESUMO

The effects of methylmercury (MeHg) and selenium (Se) contamination on food webs in the San Francisco Estuary have received considerable attention during the past decade. However, knowledge of their effects on native fishes of California is lacking. This study investigated the interactive effects of dietary MeHg and seleno-methionine (SeMet) on Sacramento splittail (Pogonichthys macrolepidotus) larvae. Twelve diets containing increasing levels of SeMet (0.64, 8.2 and 35.0 microg Se g(-1) diet) and MeHg (0.01, 0.13, 4.7 and 11.7 microg Hg g(-1) diet) were fed to 21-day post-hatch larvae for 4 weeks in 2-L beakers at 25 degrees C. Fish were fed twice a day at a feeding rate of 40, 30, 25 and 20% of body weight during the 1st, 2nd, 3rd and 4th week, respectively. At the end of week 4, no significant difference (P>0.05) was observed among treatments for mortality, body length or weight, and condition factor. Bioaccumulation of Hg and Se responded positively and significantly (P<0.05) to their dietary concentrations. The molar ratio of Se/Hg in diets was linearly correlated to the ratio of Se/Hg in fish. Dietary Se inhibited Hg accumulation, which was negatively correlated to the dietary Se/Hg ratio. Histopathological examination revealed severe gill anomaly and liver glycogen depletion in fish fed the 11.7 microg Hg g(-1) diet. Liver glycogen depletion and kidney tubular dilation were found in larvae fed the 11.7 microg Hg and 11.7 microg Hg+35 microg Se g(-1) diets. In conclusion, dietary Hg enhanced Se accumulation but dietary Se inhibited Hg accumulation in splittail. Dietary Se showed a protective effect in fish fed the high MeHg diet. This protection was related to the dietary Se/Hg ratio, which is a more reliable criterion for evaluating the interactive effect between Se and Hg in splittail.


Assuntos
Cyprinidae/crescimento & desenvolvimento , Dieta , Compostos de Metilmercúrio , Selênio , Poluentes Químicos da Água , Animais , Cyprinidae/metabolismo , Interações Medicamentosas , Brânquias/efeitos dos fármacos , Brânquias/metabolismo , Brânquias/patologia , Rim/efeitos dos fármacos , Rim/metabolismo , Rim/patologia , Larva/crescimento & desenvolvimento , Larva/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Metionina/administração & dosagem , Metionina/farmacocinética , Metionina/farmacologia , Compostos de Metilmercúrio/farmacocinética , Compostos de Metilmercúrio/toxicidade , Selênio/administração & dosagem , Selênio/farmacocinética , Selênio/farmacologia , Poluentes Químicos da Água/farmacocinética , Poluentes Químicos da Água/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...